Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials-Reference-Cited by-同舟云学术

Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials

Published:2021-10 Issue:10 Volume:21 Page:1458-1468
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Mariz Filipe Colaço,Gray Penelope,Bender Noemi,Eriksson Tiina,Kann Hanna,Apter Dan,Paavonen Jorma,Pajunen Emma,Prager Kristina M,Sehr Peter,Surcel Heljä-Marja,Waterboer Tim,Müller Martin,Pawlita Michael,Lehtinen Matti

Funder

Academy of Finland

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference44 articles.

1. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions;Durst;Proc Natl Acad Sci USA,1983

2. Human papillomaviruses;IARC Monogr Eval Carcinog Risks Hum,2007

3. Carcinogenic human papillomavirus infection;Schiffman;Nat Rev Dis Primers,2016

4. HPV-1 L1 protein expressed in COS cells displays conformational epitopes found on intact virions;Ghim;Virology,1992

5. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic;Kirnbauer;Proc Natl Acad Sci USA,1992

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?;Vaccine;2024-10

2. Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ—population-based follow-up of two cluster-randomized trials;Frontiers in Cellular and Infection Microbiology;2024-09-09

3. Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study;npj Vaccines;2024-08-13

4. Development of a human papillomavirus (HPV) multiplex immunoassay to profile HPV antibodies;Journal of Medical Virology;2024-06

5. Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose in young women aged 15–20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials;The Lancet Global Health;2024-03